Other relevant news · Mind Medicine Australia
Mind Medicine Australia logo Menu

Other relevant news

Israeli company reveals nasal spray of psychedelic mushrooms

Al-Monitor, 09 May, 2022

Madrigal Mental Care says the spray treats post-traumatic stress disorder, anxiety and other mental challenges. Some experts believe magic mushrooms have health benefits, though they come with risks.

Read more

COMP360 psilocybin therapy shows potential in exploratory open-label studies for anorexia nervosa and severe treatment-resistant depression

Globe News Wire, 03 May, 2022

Positive early signals seen in two investigator-initiated studies presented at the Society of Biological Psychiatry Annual Meeting in New Orleans.

Read more

Trending Clinical Topic: Psychedelics

MedScape, 22 April, 2022

A new study examined changes in specific neurotransmitter systems and brain regions that may be responsible for various experiences associated with a psychedelic “trip”.

Read more

Australian researchers trialling magic mushroom active ingredient as antidepressant

9 News, 27 April, 2022

Sydney researchers are testing psilocybin as an alternative to antidepressants.

Read more

GoDaddy Billionaire Bob Parsons Believes Psychedelics Can Heal Trauma—And He’s Putting His Money (And Brain) On The Line

Forbes, 17 April, 2022

The Marine infantryman still suffers from PTSD from his tour in Vietnam but credits LSD and MDMA with helping him “come home.” Now he’s on a mission to help other veterans.

Read more

‘Magic mushrooms’ for PTSD therapy? Vets help sway conservatives

LA Times, 16 April, 2022

Matthew Butler spent 27 years in the Army, but it took a day in jail to convince him that his post-traumatic stress disorder was out of control.

Read more

Mushrooms’ magic compound latest hope to relieve depression

The Australian, 12 April, 2022

Early tests show lasting effects of brain ‘rewiring’ following controlled ‘trips’

Read the full PDF.

Read more

Psychedelic frees up depressed brain, study shows

BBC News, 12 April, 2022

Psilocybin appears to free up the brains of people with severe depression in a way that other antidepressants do not, a study has found.

Read more

What the science says about microdosing

Australian Financial Review, 08 April, 2022

Scientists have insight into what happens when someone takes enough psychedelics to experience hallucinogenic effects. But little research has been conducted on the effects of small doses.

Read the full PDF here.

Read more

6 terminally ill cancer patients in Canada received doses of the psychoactive substance found in 'magic' mushrooms after authorities eased rules

Business Insider, 07 April, 2022

Six terminally ill cancer patients in Canada received the country’s first legally produced psilocybin under new rules about access to the substance.

Read more

Psychedelics may ease cancer patients’ depression, anxiety

Washington Post, 02 April, 2022

Evidence indicates that psychedelics could reduce the end-of-life anxiety that many cancer patients experience.

Read more

The Next Big Addiction Treatment

New York Times, 31 March, 2022

Psilocybin combined with therapy is emerging as one of the most effective psychedelic therapies.

Read the PDF article here.

Read more

Why microdosing is gaining momentum in Australia

Australian Financial Review, 24 March, 2022

Microdosing psychedelic drugs has been a trend in Silicon Valley that’s taking off here. But does a micro trip help you make better decisions at work?

Read the full PDF article here.

Read more

LSD, a future anti-anxiety pill?

McGill University Health Centre, 18 March, 2022

A study conducted by Gabriella Gobbi, MD, Professor and Head of the Neurobiological Psychiatry Unit in the Department of Psychiatry, and her team demonstrates for the first time that regular administration of low doses of LSD (lysergic acid diethylamide) reduces anxiety symptoms through neurobiological mechanisms that are similar to those of selective serotonin reuptake inhibitors (SSRIs).

Read more

Johns Hopkins, Yale, and NYU are teaming up to tackle a key bottleneck that will arise as psychedelics come to market

Business Insider, 11 March, 2022

As psychedelics treatments move closer to regulatory approval, there’s an issue looming in the industry: the lack of trained professionals who can handle such powerful compounds.

Read more

MDMA-assisted psychotherapy for PTSD could save the health care system millions of dollars, study suggests

PsyPost, 11 March, 2022

New research provides evidence that MDMA-assisted psychotherapy can improve and extend lives of patients with chronic and severe post-traumatic stress disorder while also reducing healthcare costs.

Read more

Oklahoma House Passes Psilocybin Decriminalization Bill

Psychedelics Spotlight, 09 March, 2022

On Monday, the state’s Republican-controlled House of Representatives voted overwhelmingly, 62-30, to pass House Bill 3414, introduced by Rep. Daniel Pae (R).

Read more

4 Signs the Psychedelics Movement Is Unstoppable

Psychedelics Spotlight, 28 February, 2022

Dr. Nora Volkow, the Director of the National Institute on Drug Abuse, said earlier this year that the psychedelics “train has left the station,” and here are four big reasons to agree wholeheartedly.

Read more

Psilocybin Treatment for Major Depression Effective for up to a Year for Most Patients

Neuroscience News, 15 February, 2022

The antidepressant effect of psilocybin-assisted therapy, in combination with psychotherapy, appears to provide up to a year of symptom relief for some patients with major depressive disorder.

Read more

Two doses of psilocybin may ease depression symptoms for up to 12 months

News Medical, 15 February, 2022

Previous studies by Johns Hopkins Medicine researchers showed that psychedelic treatment with psilocybin relieved major depressive disorder symptoms in adults for up to a month. Now, in a follow-up study of those participants, the researchers report that the substantial antidepressant effects of psilocybin-assisted therapy, given with supportive psychotherapy, may last at least a year for some patients.

Read more

Plant-based Medicines

Colorado General Assembly, 10 February, 2022

Concerning establishing a policy review panel to study plant-based medicines to support mental health.

Read more

Psychedelics and the Future of Psychiatry

Psychiatric Times, 09 February, 2022

Over the past several years, we have witnessed a psychedelic renaissance, and a growing body of evidence suggests that several psychedelic compounds hold strong therapeutic potential for a wide array of mental health conditions.

Read more

Psychedelic therapy shows great promise. More states should legalise it

The Economist, 29 January, 2022

Oregon’s trailblazing sets a fine example.

Read the full PDF article here.

Read more

Sensible policy on psychedelic drugs is growing more common

The Economist, 29 January, 2022

They show tremendous potential in treating certain mental health disorders.

Read the full PDF article here.

Or listen to the topic being discussed on The Economist Podcast.

Read more

The Future of Psychedelic Medicine Will Be Drugs You’ve Never Heard Of

VICE, 25 January, 2022

Scientists are designing new psychedelic-inspired drugs that don’t yet exist, which might have effects no one can yet describe.

Read more

Ketamine for the treatment of alcoholism

Blossom Analysis, 24 January, 2022

Psychedelics are poised to be both viable and effective treatment options for many people living with mental disorders whom conventional treatments have failed. One of these disorders is substance use disorder (SUD), commonly known as addiction.

Read more

Psychedelics Offer New Route to Recovery from Eating Disorders

Neo.Life, 01 February, 2022

Psilocybin, MDMA, and ketamine can lead to a new sense of self and a release from rigid rules for people with anorexia, bulimia, and binge-eating disorder.

Read more

How 2021 became the year of psychedelics – and why 2022 is set to be even bigger

Canex, 20 January, 2022

It’s no secret that psychedelics are on the comeback trail, with a record number of trials and total investment in the hundreds of millions of dollars in 2021 alone.

Read more

How magic mushrooms changed my life

Financial Review (AFR), 19 January, 2022

So, can psilocybin really help those with depression? I was skeptical, but the retreat changed my mind.

Read the PDF article here.

Read more

Health Canada’s New SAP Rules: A Q&A With Numinus’ Payton Nyquvest

Psychedelic Stock Watch, 10 January, 2022

In 2020, Health Canada began tentative steps to open up legal access to psychedelics-based therapies via “exemptions” granted through its Special Access Program (SAP).

Details from the program can be found here.

Read more

$14.8 million for innovative mental health clinical trials

Health.gov.au, 07 January, 2022

Seven clinical trials testing the use of potential breakthrough combination therapies to treat debilitating mental illnesses will receive a total of almost $15 million from the Australian Government’s Medical Research Future Fund (MRFF).

Read more

Therapists hail 'legalization' of medicinal psychedelic drugs

Calgary Herald, 07 January, 2022

Local therapists say Ottawa’s move allowing physicians to prescribe psychedelics is a “seismic shift” towards legalizing their medicinal use.

Read more

Canada Opens New Legal Pathways For Access To Psychedelics Treatment With Psilocybin And MDMA

Benzinga, 05 January, 2022

In a groundbreaking decision, the Canadian government is changing the way patients can access psychedelic therapies with restricted drugs, including MDMA and psilocybin.

Read more

Depression and Grief Wrecked a Man's Life—Until He Took Magic Mushroom Ingredient

Newsweek, 26 December, 2021

Five years after taking part in a clinical trial, Kirk Rutter, spoke to Newsweek about his experiences of the trial and its impact on his mental health.

Read more

New center to study psychedelics pops up at University of Texas at Austin

My Sanantonio, 20 December, 2021

The Dell Medical School at the University of Texas at Austin is launching the Center for Psychedelic Research and Therapy, the first-of-its-kind center dedicated to the research of drugs such as psilocybin mushrooms, ayahuasca, MDMA, and ibogaine.

Read more

New Filing Challenges Compass Pathways’ Infamous Patent on Synthetic Psilocybin

VICE, 16 December, 2021

The non-profit Freedom to Operate used research from chemists and crystallographers to argue in a legal filing that Compass’ form of synthetic psilocybin is not a new invention.

Read more

Exclusive: Three Canadians with mental health conditions receive legal access to psilocybin mushrooms

The Growth Op, 13 December, 2021

Three Canadians struggling with mental health conditions have received exemptions to the Controlled Drugs and Substances Act from the federal Minister of Health Jean-Yves Duclos.

Read more

'This isn’t the 60s again’: psychedelics business takes off amid culture clash

The Guardian, 12 December, 2021

Experts fear if psychedelics fall exclusively into the hands of big pharma the industry will follow the same path as legal marijuana, making the rich richer.

Read more

Psychedelics for mental illness

ABC All in the Mind, 12 December, 2021

Major trials are bringing us a step closer to seeing psychedelic substances used in therapy practice for PTSD, anxiety and depression. On this episode of All in the Mind, we take a look at where the research is currently at with our Ambassadors Dr Rick Doblin and Professor David Nutt.

Read more

Psychedelics can change humanity for the better. It’s time to unlock their power

The Guardian, 26 November, 2021

Founder and Executive Director at MAPS and an Ambassador for Mind Medicine Australia, Dr Rick Doblin (USA) is at the heart of the psychedelic movement. In this article he shares some of his findings and progress.

Read more

Doctor takes bid to treat patient with MDMA to court, in first case of its kind in Australia

ABC News, 12 November, 2021

There’s growing interest in the use of psychedelic medicine in the treatment of complex mental health disorders like depression and PTSD.

Read more

New research brings psychedelic drugs a step closer to medical use

ABC: RN Breakfast with Fran Kelly, 10 November, 2021

There’s growing interest in the use of psychedelic medicine in the treatment of complex mental health disorders like depression and PTSD.

Read more

Monash presses go on psychedelics to tackle ‘mental health tsunami’

The Sydney Morning Herald, 10 November, 2021

Monash University has set its sights on capturing a slice of the multibillion dollar psychedelic medicines market, with the launch of a drug development centre for new psychiatric treatments, including those using MDMA and psilocybin.

Read more

Major announcement: COMPASS Pathways announces positive topline results from groundbreaking phase IIb trial of investigational COMP360 psilocybin therapy for treatment-resistant depression

Globenewswire, 09 November, 2021

Largest randomised, controlled, double-blind psilocybin therapy study ever completed shows rapid and sustained response for patients receiving a single dose of COMP360 psilocybin with psychological support.

Read more

Will the magic of psychedelics transform psychiatry?

The Guardian, 07 November, 2021

Imagine a medicine that could help people process disturbing memories, sparking behavioural changes rather than merely burying and suppressing symptoms and trauma.

Read more

New research shows how psychedelic medicines can help people with PTSD

Today.com, 05 November, 2021

TODAY’s Savannah Guthrie spoke to two patients whose lives have been changed by the therapy.

Read more

World-first trial of psilocybin therapy for anxiety disorders to begin in Australia

Happymag, 01 November, 2021

Incannex Healthcare, in partnership with Monash University, has obtained ethics approval to begin the first-ever clinical trial investigating the effects of psilocybin assisted psychotherapy to treat generalised anxiety disorder (GAD).

Read more

Johns Hopkins Receives $4M From NIH To Study Psilocybin As Tool To Quit Smoking

Ganjapreneur, 22 October, 2021

Baltimore’s Johns Hopkins Medicine announced that the National Institutes of Health will provide nearly $4 million to help researchers study how psilocybin can affect tobacco addiction.

Read more

DEA Wants Way More Cannabis & Psychedelics for Research In 2022

Ganjapreneur, 18 October, 2021

The DEA has proposed massively increasing the production of research-grade cannabis and psychedelics like LSD, psilocybin, and MDMA next year.

Read more

Psychedelic research renaissance: The urgent quest for new mental health medicines

Lens Monash, 15 October, 2021

“There’s been a resurgence in research and interest in psychedelic medicine over the past two decades, and particularly so over the past five years,” says Dr Liknaitzky.

Read more

Could mushrooms, molly and acid be the new wave of mental health care?

NBC News, 13 October, 2021

Doctors are looking into psychedelics to possibly reduce anxiety and depression. NBC News’ Maya Eaglin reports on the new wave of mental health care.

Read more

National anxiety crisis worsens

The Australian, 03 October, 2021

Australians are reporting depression, anxiety and stress at higher rates than the same time last year, with four in five experiencing poor mental health, and children and young people the most seriously affected, as pandemic uncertainty and lockdowns continue to take a toll.

Read the PDF article here.

Read more

Psychedelic biotech Psylo raises first funds

The Australian, 01 October, 2021

There’s a growing pool of funds being invested in psychedelic research.

Read the PDF here.

Read more

Psychedelics might reduce internalized shame and complex trauma symptoms in those with a history of childhood abuse

Psypost.org, 30 September, 2021

The use of psychedelic medicines is associated with lower levels of complex posttraumatic stress symptoms and internalized shame in adults who suffered maltreatment in childhood, according to new research published in the journal Chronic Stress.

Read more

Magic Mushrooms May Be the Biggest Advance in Treating Depression Since Prozac

Newsweek, 22 September, 2021

Psilocybin could be the biggest advance since Prozac.

Read more

Small pharma successfully completes phase 1 clinical trial of DMT in combination with supportive psychotherapy

Smallpharma.co.uk, 21 September, 2021

Small Pharma’s DMT-assisted therapy (SPL026) demonstrated to be well-tolerated and safe in psychedelic naïve volunteers.

Read more

Medicinal cannabis company Little Green Pharma gets green light for psychedelic drug production

ABC News, 10 September, 2021

A WA-based medicinal cannabis company has been given regulatory approval to produce psilocybin, a hallucinogenic substance found in magic mushrooms, to supply for medical research.

Read more

The worldview-changing drugs poised to go mainstream

BBC, 07 September, 2021

Our Ambassador Dr Rick Doblin (USA) is featured in this article by the BBC: The worldview-changing drugs poised to go mainstream.

Read more

Suicide line records highest number of calls in history

The Australian, 20 August, 2021

Australia’s biggest suicide support line has recorded the most calls for help it has ever received in one day, amid concerns about long-term mental health consequences of Covid-19 restrictions.

Read the article here or the PDF attached.

Download (233.3 KB)

TGA appoints Independent Expert Panel on MDMA and psilocybin

TGA, 05 August, 2021

The Therapeutic Goods Administration (TGA) Scheduling Delegate (decision maker) has deferred the final decision on applications to down-schedule MDMA and psilocybin from schedule 9 (prohibited drug) to schedule 8 (controlled drug) pending a review into the therapeutic value, risks and benefits to public health outcomes for these substances. The Independent Expert Panel to undertake this review has now been established.

Read more

Canadians Overwhelmingly Support Legal Access to Psilocybin-Assisted Therapy, Poll Reveals

Psilocybin Alpha, 04 August, 2021

A new poll, commissioned by the Canadian Psychedelic Association, has highlighted widespread support for legal access to psilocybin-assisted therapy among Canadians.

Read more

New Yale Study Shows Psilocybin Spurs Growth of Neural Connections Lost in Depression

Microdose.buzz, 03 August, 2021

A new study conducted by researchers at Yale University showed psilocybin can facilitate the regrowth of neurons lost in depression.

Read more

Just One Dose of Magic Mushroom Compound Regrows Lost Brain Connections in Mice

Science Alert, 06 July, 2021

Psilocybin, the active psychedelic compound, has some curious effects on the human brain.

Read more

Psychedelic IPOs build momentum as Atai Life Sciences goes public

PitchBook, 18 June, 2021

Making its Wall Street debut, Peter Thiel-backed Atai Life Sciences has become the third biotech company focused on psychedelic treatment for mental health disorders to list on a major US stock exchange.

Read more

My team’s research shows magic mushrooms treat depression, but undoing the stigma will be a bigger challenge

iNews, 03 June, 2021

Bringing psychedelic therapy into mainstream treatment will present some major challenges.

Read more

Magic mushroom microdosing: Kiwis call for 'life-saving' treatment to be legalised | Newshub Nation

Newshub, 01 June, 2021

Everyday Kiwis with devastating illnesses are turning to small doses of psychedelic medicines to find relief and are calling for a ‘life-saving’ treatment to be made legal for medical purposes.

Read more

Ketamine a game changer in treating eating disorders

Toronto Sun, 29 May, 2021

Ketamine, MDMA and psilocybin are proving useful with treatment-resistant mental illnesses, including eating disorders.

Read more

Magic mushroom microdosing: Sick Kiwis call for 'life-saving' Class-A drug to be legalised

Newshub, 29 May, 2021

Every day Kiwis with devastating illnesses are turning to small doses of psychedelics to find relief and are calling for what they call a ‘life-saving’ treatment to be made legal for medical purposes.

Read the full PDF here.

Read more

Algernon Pharmaceuticals Highlights New Animal Study Showing Effectiveness of Psychedelic Drug DMT in Treatment of Stroke

Globe News Wire, 27 May, 2021

Algernon recently established a clinical research program for the treatment of stroke focused on DMT.

Read more

Could the ‘spirit molecule’ be a treatment option for stroke?

Vancouver Sun, 25 May, 2021

Researchers have spent decades and billions of dollars unsuccessfully searching for novel treatments for stroke. Now a Vancouver-based company is putting a unique hypothesis to the test.

Read more

Who’s in Charge of Psilocybin?

Chacruna, 10 May, 2021

From clinicians and investors to Indigenous groups and activists, debate is raging over whether psychedelics are spiritual tools, new psychiatric drugs, medicines for social change, or all of the above.

Read more

Psychedelic medicine is about to blow up

Fast Company, 11 May, 2021

New clinical data shows that MDMA-assisted therapy can have a significant impact on PTSD, paving the way for FDA approval and commercialization.

Read more

The Psychedelic Revolution Is Coming. Psychiatry May Never Be the Same.

The New York Times, 09 May, 2021

Psilocybin and MDMA are poised to be the hottest new therapeutics since Prozac. Universities want in, and so does Wall Street. Some worry a push to loosen access could bring unintended consequences.

Read the PDF here.

Read more

Legalise 'magic mushrooms' to help cure depression, says London scientist

My London, 06 May, 2021

The director of a pioneering psychedelic research centre on the benefits and limitations of psychedelics for depression.

Read more

A Psychedelic Drug Passes a Big Test for PTSD Treatment

The New York Times, 03 May, 2021

A new study shows that MDMA can bring relief when paired with talk therapy to those with severe post-traumatic stress disorder.

Read the PDF version here.

Read more

MAPS’ Phase 3 Trial of MDMA-Assisted Therapy for PTSD Achieves Successful Results for Patients with Severe, Chronic PTSD

Maps.org, 03 May, 2021

The first Phase 3 trial of MDMA-assisted therapy for posttraumatic stress disorder (PTSD) replicated and expanded on Phase 2 results indicating MDMA-assisted therapy may be an effective and cost-saving treatment for PTSD resulting from any cause.

Read more

There Is a Lot of Fungus Among Us

The New York Times, 24 April, 2021

Coffee for immune support. Supplements for inflammation. And psychedelics promising relief from serious ailments. Mushrooms are everywhere, and investors are paying attention.

Read more

Massachusetts General Hospital Launches Center to Study Neuroscience of Psychedelics

The Crimson, 23 April, 2021

Massachusetts General Hospital, an affiliate of Harvard Medical School, launched a new center to study the clinical benefits of psychedelics in treating mental illness.

Read more

Subscribe to our newsletter

Stay in touch with Mind Medicine Australia:

It's time. Make your voice heard. Lodge a submission to the TGA supporting rescheduling of MDMA and Psilocybin. Closes May 27.